CoChat
Sign Up
Cited by 49Systemic Lupus Erythematosus ResearchVasculitis and related conditionsSystemic Sclerosis and Related Diseases

IgM Anti-ß2Glycoprotein I Is Protective Against Lupus Nephritis and Renal Damage in Systemic Lupus Erythematosus

MEHRANI, TARANEH, PETRI, MICHELLE·2011·The Journal of Rheumatology
DOI 10.3899/jrheum.100650
Open this paper in CoChat — free account

Abstract

OBJECTIVE: Antibodies to ß(2) glycoprotein I (IgG and IgM isotypes) have recently been added to the laboratory criteria of the revised antiphospholipid syndrome classification criteria. We investigated whether IgM anti-ß(2)-glycoprotein I (anti-ß(2)-GPI) is associated with clinical manifestations of systemic lupus erythematosus (SLE). METHODS: Anti-ß(2)-GPI was measured in 796 patients with SLE (93% women, 53% white, 38% African American, mean age 45 yrs). IgM anti-ß(2)-GPI (> 20 phospholipid units) was found in 16%. Associations were determined with clinical manifestations of SLE and with components of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. RESULTS: As expected, IgM anti-ß(2)-GPI was highly associated with both the lupus anticoagulant and with anticardiolipin. It was associated with transient ischemic attack (OR 2.64, p = 0.04), but not significantly with venous or arterial thrombosis. IgM anti-ß(2)-GPI was protective against lupus nephritis (OR 0.54, p = 0.049), renal damage (p = 0.019), and hypertension (OR 0.58, p = 0.008). This protective effect remained after adjustment for ethnicity. CONCLUSION: In SLE, IgM anti-ß(2)-GPI is not associated with thrombosis but is protective against lupus nephritis and renal damage. "Natural" autoantibodies of the IgM isotype may have a protective effect.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3899/jrheum.100650

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Large studies found that IgM aCL and IgM anti-β2-glycoprotein I are not associated with thrombotic events.

    “Large studies found that IgM aCL and IgM anti-β2-glycoprotein I are not associated with thrombotic events [9–13].”

    From Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus (2021) · cites this paper as [11]

    In 796 patients with SLE, the Results (p. 2) report no significant association between IgM anti-β2-GPI and venous or arterial thrombosis. The table (p. 3) likewise shows no significant association between IgM aCL and the listed venous thromboses, stroke, or myocardial infarction. But both antibodies were significantly associated with transient ischemic attack, so the unqualified claim about thrombotic events is too broad. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • In SLE, IgM isotypes were not found to be associated with thrombosis.

    “In SLE, IgM isotypes were not found to be associated with thrombosis [11, 13].”

    From Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus (2021) · cites this paper as [11]

    The Results and Discussion (p. 2) report that IgM anti-β2-GPI was not significantly associated with venous or arterial thrombosis in patients with SLE; the table on p. 3 likewise shows no significant thrombosis association for IgM anticardiolipin. The claim extends those findings to IgM isotypes generally, which this paper does not establish. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

  • IgM aCL is not associated with lifetime thrombosis risk in SLE.

    “Moreover, it has been shown that IgM aCL is not associated with lifetime thrombosis risk in SLE [10, 11].”

    From Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus (2021) · cites this paper as [11]

    The IgM aCL rows of Table 1 (p. 3) show no significant association with most listed thrombotic outcomes, including deep venous thrombosis and stroke. But they show a significant association with transient ischemic attack (OR 2.44, p = 0.0389), so the blanket claim of no association is too broad. The table reports these outcomes, not a single measure of lifetime thrombosis risk. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [21]21. Bombardier C, Gladman DD, Chang CH, Urowitz MB, and the Committee on Prognosis Studies in SLE. Development of the Disease Activity Index: the SLEDAI. Arthritis Rheum 1992;35:630-40.
  2. [27]27. Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies. Arthritis Rheum 2004;50:2569-79.

Cited by

Sorted by citations

Related

Authors
MEHRANI, T., & PETRI, M.
Affiliations
Johns Hopkins University (US)
Corresponding author
PETRI, MICHELLE
ORCID
PETRI, MICHELLE
Venue
The Journal of Rheumatology
Publisher
The Journal of Rheumatology
Published
2010-12-01
Volume
38
Issue
3
Pages
450-453
ISSN
  • 0315-162X (ISSN-L)
  • 1499-2752
DOI
10.3899/jrheum.100650
OpenAlex
W2013908722
Cited by
49
References
39
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 4 · 2017: 3 · 2016: 7 · 2015: 1 · 2014: 4 · 2013: 4 · 2012: 8
FWCI
2.90
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Rheumatology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR043727)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vasculitis and related conditions
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Systemic Sclerosis and Related Diseases
Keywords
systemic lupus erythematosus, lupus nephritis, kidney injury, lupus anticoagulant, anticardiolipin antibodies, thrombosis, transient ischemic attack, hypertension, antiphospholipid syndrome, natural autoantibodies, SLE damage index
MeSH terms
Adult, Aged, Aged, 80 and over, Female, Humans, Immunoglobulin M, Kidney, Lupus Erythematosus, Systemic, Lupus Nephritis, Middle Aged, Lupus Coagulation Inhibitor, Antibodies, Anticardiolipin, beta 2-Glycoprotein I, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review